Policosanol in patients with metabolic syndrome and ischaemic cardiopaty

Phase 4

Not yet recruiting

• Conditions: Metabolic Syndrome and ischaemic cardiopaty; Myocardial Ischemia; Oxidative Stress; Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Heart Diseases; Vascular Diseases

• Registration Number: RPCEC00000227
• Lead Sponsor: Center of Natural Products, National Center for Scientific Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-12-27
• Last Update Posted: 2024-08-19

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1) Patients with ischaemic cardiopaty.
2) Both sexes.
3) Age: 25-70 years
4) Diagnostic of metabolic syndrome by NCEP-ATP III criteria

Exclusion Criteria

1) Consuming policosanol or other lipid lowering drug and antioxidant or pro-oxidant medications, six months period previus study.
2) Ischaemic or haemorragic ictus.
3) Mayor surgery six mionths previusat study begining.
4) Cardiac insuficience.
5) Hepatic insuficience.
6) Neoplasms diagnosed.
7) Alcoholism.
8) Psyquiatric problems.
9) Patients with clinical history of allergy to any other medicines or other conditions that endanger their health and their lives during the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified